Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease
Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
Sickle cell disease (SCD) is an inherited blood disorder that causes the red blood cells to
change their shape from a round shape to a half-moon/crescent or sickled shape. People who
have SCD have a different type of protein that carries oxygen in their blood (hemoglobin)
then people without SCD. This different type of hemoglobin makes the red blood cells change
into a crescent shape under certain conditions. Sickle-shaped cells are a problem because
they often get stuck in blood vessels blocking the flow of blood, and cause inflammation and
injury to the important areas in the body. Lexiscan is drug that may prevent this
inflammation and injury caused by the sickle shaped cells. This drug is approved by the FDA
to be used as a fast infusion during a heart stress test in people who are unable to exercise
enough to put stress on their heart by making it beat faster. Lexiscan has never been studied
in patients with SCD and has never been given as a long infusion.
Phase:
Phase 1
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Astellas Pharma Global Development, Inc. Boston Children's Hospital Boston Children’s Hospital Brigham and Women's Hospital Johns Hopkins University La Jolla Institute for Allergy & Immunology Medical College of Wisconsin National Heart, Lung, and Blood Institute (NHLBI) Washington University School of Medicine